Llamas-Velasco, MarHospital, MercedesLopez-Ferrer, AnnaHerranz, PedroRuiz-Villaverde, RicardoMateu, AlmudenaGarcia-Latasa, Francisco JavierRivera, RaquelFernandez-Freire, Lourdes RodriguezAlcazar, Elena DelSantos, SergioArias, SalvadorGonzalez-Cantero, AlvaroBelinchon, IsabelCarretero, GregorioFerran, MartaRuiz-Genao, DianaEiris, NoemiSahuquillo, AntonioMataix, JavierCarrascosa, Jose-MariaCueva, Pablo de laSalgado-Boquete, Laura2026-08-032026-08-032026-04-24Llamas-Velasco, M, Hospital, M, Lopez-Ferrer, A, Herranz, P, Ruiz-Villaverde, R, Mateu, A, Garcia-Latasa, F J, Rivera, R, Fernandez-Freire, L R, Alcazar, E D, Santos, S, Arias, S, Gonzalez-Cantero, A, Belinchon, I, Carretero, G, Ferran, M, Ruiz-Genao, D, Eiris, N, Sahuquillo, A, Mataix, J, Carrascosa, J-M, Cueva, P D L & Salgado-Boquete, L 2026, 'Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)', Pharmacy, vol. 14, no. 3, 63. https://doi.org/10.3390/pharmacy140300632226-4787PubMedCentral: PMC13214649unpaywall: 10.3390/pharmacy14030063https://hdl.handle.net/10641/8237131727504enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Biological therapyElderlyPsoriasisReal-world evidenceTildrakizumabJournal ArticleYesjournal articleopen access10.3390/pharmacy14030063https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure24ufv&SrcAuth=WosAPI&KeyUT=WOS:001803681900001&DestLinkType=FullRecord&DestApp=WOS_CPL